← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
A And G Pharmaceutical, Inc.
Columbia, MD
$11,064,665
Total funding
17
Grants
Funding over time
peak $2.1M · FY2007–24$2.5M$1.9M$1.3M$625K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$11,064,665 · 17
By mechanism
R44$6,504,218 · 4
N44$2,478,552 · 2
R43$864,377 · 6
R01$441,000 · 1
N43$399,208 · 2
N01$238,533 · 1
Investigators at A And G Pharmaceutical, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
DEVELOPMENT OF NOVEL ANTICANCER AGENT TO POTENTIATE SENSITIVITY TO ANTI-ESTROGEN THERAPY$1,478,552
N44 · FY2014 · CA
Targeted Therapy for Non Small Cell Lung Carcinoma: Human Phase 1 safety and dose escalation studies$1,154,726
R44 · FY2017 · CA
A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer$1,101,350
R44 · FY2018 · CA
Pharmacology & human Phase 1 safety & dose escalation studies using anti-GP88 in aggressive breast cancer$1,062,115
R44 · FY2020 · CA
IGF::OT::IGF SMART FUSION: HIGH AFFINITY PEPTIDE CAPTURE REAGENTS$1,000,000
N44 · FY2015 · CA
Targeted Therapy for Non Small Cell Lung Carcinoma: Human Phase 1 safety and dose escalation studies$833,374
R44 · FY2018 · CA
Pharmacology & human Phase 1 safety & dose escalation studies using anti-GP88 in aggressive breast cancer$826,939
R44 · FY2022 · CA
Novel Targeted Therapy for Breast Cancer$578,078
R44 · FY2011 · CA
Novel Targeted Therapy for Breast Cancer$575,793
R44 · FY2010 · CA
PC CELL DERIVED GROWTH FACTOR IN HUMAN BREAST CANCER$253,575
R01 · FY2003 · CA
IGF::OT::IGFTitle: SMART Fusion: High Affinity Peptide Capture ReagentsPoP: 0$199,828
N43 · FY2013 · CA
NOVEL AGENT TO RESTORE SENSITIVITY TO ANTI-ESTROGEN THERAPY$199,380
N43 · FY2012 · CA
Targeted Therapy for Non Small Cell Lung Carcinoma: In vivo Feasibility Studies$193,879
R43 · FY2012 · CA
PC CELL DERIVED GROWTH FACTOR IN HUMAN BREAST CANCER$187,425
R01 · FY2004 · CA
Novel Small Molecule Inhibitor of Rheumatoid Arthritis$184,029
R43 · FY2009 · AI
Pharmacology & human Phase 1 safety & dose escalation studies using anti-GP88 in aggressive breast cancer$159,365
R44 · FY2018 · CA
A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer$152,589
R43 · FY2017 · CA
A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer$141,660
R44 · FY2021 · CA
Novel Targeted Therapy for Breast Cancer$120,600
R43 · FY2007 · CA
TO6 - GENERATING MONOCLONAL CELL LINES, MONOCLONAL ANTIBODIES, AND LABELED MONOCLONAL ANTIBODIES AGAINST HUMAN AND MOUSE COLQ$116,400
N01 · FY2023 · DA